- Veteran bands Motorhead, Black Sabbath top Metal Hammer Golden Gods
- Analysis - French EU-wariness complicates life for Hollande
- Vodafone may trump Liberty with $10 billion cash bid for Kabel - sources
- Golfing in Iceland's midnight sun - lava beds, angry birds, winds
- BoE, still divided, flags market impact of Fed uncertainty
Sanofi Q4 profit falls 24 percent, growth to return in H2
PARIS (Reuters) - Sanofi (SASY.PA) reported a 24 percent decline in fourth-quarter profit on Thursday and predicted growth would resume in the second half of 2013 once the impact of drug patent losses eases.
The French drugmaker said earnings in 2013 would be flat to 5 percent lower than in 2012 at constant exchange rates and that it was on track to meet its mid-term targets.
Business net income, which excludes items such as amortisation and legal costs, declined 24.3 percent to 1.57 billion euros ($2.1 billion) in the fourth quarter, the group said in a statement.
Sales in the period rose 0.2 percent to 8.53 billion euros as the impact from austerity measures in Europe and generic competition offset favourable currency moves and growth from rare disease unit Genzyme.
Sanofi was expected to post quarterly business net income of 1.54 billion euros on sales of 8.56 billion, according to Thomson Reuters I/B/E/S estimates.
(Reporting by Elena Berton; Editing by James Regan)
- Tweet this
- Share this
- Digg this